COVID-19 Competitive Landscape

DelveInsight’s, “COVID 19 - Competitive landscape, 2025,” report provides comprehensive insights about 100+ companies and 110+ drugs in COVID 19  Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.  

Geography Covered

• Global coverage

COVID-19: Understanding

COVID-19: Overview

COVID-19 is an infectious disease caused by a newly discovered coronavirus. It can affect your upper respiratory tract (sinuses, nose, and throat) or lower respiratory tract (windpipe and lungs). It spreads the same way other coronaviruses do, mainly through person-to-person contact. Infections range from mild to deadly. The main symptoms include:  Fever , Coughing, Shortness of breath, Trouble breathing, Fatigue, Chills, sometimes with shaking, Body aches, Headache, Sore throat, Congestion/runny nose, Loss of smell or taste, Nausea, Diarrhea. The virus can lead to pneumonia, respiratory failure, heart problems, liver problems, septic shock, and death. Many COVID-19 complications may be caused by a condition known as cytokine release syndrome or a cytokine storm. This is when an infection triggers your immune system to flood your bloodstream with inflammatory proteins called cytokines. They can kill tissue and damage your organs. 

SARS-CoV-2, the virus, mainly spreads from person to person. Most of the time, it spreads when a sick person coughs or sneezes. They can spray droplets as far as 6 feet away. If you breathe them in or swallow them, the virus can get into your body. Some people who have the virus don't have symptoms, but they can still spread the virus. You can also get the virus from touching a surface or object the virus is on, then touching your mouth, nose, or possibly your eyes. Most viruses can live for several hours on a surface that they land on. A study shows that SARS-CoV-2 can last for several hours on various types of surfaces: Copper (pennies, teakettles, cookware): 4 hours, Cardboard boxes: up to 24 hours, Plastic (milk containers, detergent bottles, subway and bus seats, elevator buttons):2 to 3 days, Stainless steel (refrigerators, pots and pans, sinks, some water bottles): 2-3 days. 

Anyone can get COVID-19, and most infections are mild. The older you are, the higher your risk of severe illness. You also a have higher chance of serious illness if you have one of these health conditions: Chronic kidney disease, chronic obstructive pulmonary disease (COPD), a weakened immune system because of an organ transplant, obesity, serious heart conditions such as heart failure or coronary artery disease, sickle cell disease, Type 2 diabetes.

Conditions that could lead to severe COVID-19 illness include: Moderate to severe asthma, diseases that affect your blood vessels and blood flow to your brain, cystic fibrosis, high blood pressure, a weakened immune system because of a blood or bone marrow transplant, HIV, or medications like corticosteroids, dementia, liver disease, pregnancy, damaged or scarred lung tissue (pulmonary fibrosis), smoking, thalassemia, Type 1 diabetes. 

Getting vaccinated against COVID-19 is a key part of prevention. But one should also take these steps: Washing hands often with soap and water or clean them with an alcohol-based sanitizer, practice social distancing, covering nose and mouth in public, don’t touch face, clean and disinfect. 

COVID-19 Report Highlights

• In June 2024, The Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services (HHS), is announcing up to $500 million in Project NextGen funding to plan and execute multiple Phase II b clinical trials evaluating novel vaccines administered as a nasal spray or as a pill to protect against symptomatic COVID-19.
• In March 2024, Ensitrelvir had demonstrated both antiviral efficacy and clinical symptomatic efficacy against common COVID-19 symptoms in a predominantly vaccinated population with mild to moderate disease. Results captured in the Phase III clinical trial (SCORPIO-SR) suggest that treatment with ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor developed by Shionogi & Co., Ltd, shortens the duration of 5 common COVID-19 symptoms in patients with mild to moderate disease.
• In March 2024, Moderna announced promising interim Phase III clinical trial findings for its next-generation COVID vaccine, which offers the potential for a longer shelf life and paves the way for a combination mRNA vaccine against flu and COVID.
• In January 2024, Vaxart had announced a funding boost for its oral Covid-19 vaccine candidate, with the US Biomedical Advanced Research and Development Authority (BARDA) awarding the company $9.27m.This funding is earmarked for launching a Phase IIb clinical trial of the oral pill vaccine candidate, which is set to involve around 10,000 subjects.
• In August 2023, The U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), awarded more than $1.4 billion for Project NextGen to support the development of a new generation of tools and technologies to protect against COVID-19 for years to come.
• In March 2023, Emory University announced an agreement with Pfizer Inc. to advance research that may serve to help address this need and potentially save patients’ lives.   Under the terms of the research collaboration, option and license agreement, Emory University’s Schinazi Laboratory, led by distinguished researcher Raymond Schinazi, and Pfizer will work together to identify and evaluate potential antiviral compounds for the treatment of COVID-19

COVID-19: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. As a leading healthcare company, the company is doing all to support countries in their fight against COVID-19 and minimizing its impact. The company has developed a growing number of diagnostic solutions that help to detect and diagnose the infection, as well as providing digital support to healthcare systems. The company continue to identify, develop, and support therapies that can play a role in treating the disease. It is currently working with healthcare providers, laboratories, authorities, and organizations to help make sure patients continue to receive the tests, treatment and care they need during these challenging times. Building on a longstanding tradition of partnerships, it is working together with governments and others to make healthcare stronger and more sustainable in the future

Product Description: Tocilizumab

Actemra is a monoclonal antibody that reduces inflammation by blocking the interleukin-6 receptor. In the case of COVID-19 infection, the immune system can become hyperactive, which may result in worsening of disease. Actemra does not directly target SARS-COV-2. Actemra is a prescription medication given by intravenous infusion that is FDA-approved for multiple inflammatory diseases, including rheumatoid arthritis. Actemra is approved for use in multiple territories including the European Union, Japan, Bolivia, Chile, Guatemala, Ecuador, Honduras, Hong Kong, Myanmar, Peru, Philippines, the United Kingdom and Ukraine, provisionally approved in Australia, and authorized for emergency use in Ghana, Korea and the United States for defined patients hospitalized with severe or critical COVID-19. It has also been recommended and prequalified by the World Health Organization.

2. Company Overview: Bharat Biotech

Bharat Biotech International Limited has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, BBIL has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. Having delivered more than 4 billion doses of vaccines worldwide, BBIL continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC®), Rabies, Chikungunya, Zika, Cholera, and the world’s first tetanus toxoid conjugated vaccine for Typhoid. BBIL’s commitment to global social innovation programs and the public-private partnership resulted in introducing path-breaking WHO pre-qualified vaccines such as BIOPOLIO®, ROTAVAC®, ROTAVAC® 5D, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. 

Product Description: BBV154

BBV154 is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results. BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries. BBV154 was developed in partnership with Washington University St Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy. Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, were conducted by Bharat Biotech. The Government of India partly funded product development and clinical trials through the Department of Biotechnology’s, COVID Suraksha program. In September 2022, BBV154 COVID Vaccine is the first intranasal vaccine approved by DCGI for primary immunization against COVID-19 in the 18+ age group for restricted use in emergency situation being developed in the country under Mission COVID Suraksha and adds to our repertoire of COVID-19 vaccine.

COVID 19: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Bioxytran Inc.

Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment.

Product Description: ProLectin-M

ProLectin-M is an oral galectin antagonist that prevents the entry of the SARS-CoV-2 virus into human cells. In recent clinical trials the drug achieved a 100% responders rate of negative PCR tests by day 7. In 3 days, the drug achieved an 88% responders rate of negative PCR tests. The treated population experienced no viral rebounds during the 14-day observation period. The company is preparing for a phase 3 clinical trial in order to seek regulatory approval. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of COVID-19.

2. Company Overview: Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Product Description: Obeldesivir

Obeldesivir (GS-5245) is an experimental small molecule oral antiviral that shows promise as a new weapon in the arsenal against future pandemics. Several researchers from the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health have co-authored a recent study, published online in the journal Science Translational Medicine on May 22, detailing the findings of this innovative drug. The drug, obeldesivir and previously known as GS-5245, is designed to keep the coronavirus that causes COVID from replicating in the body and overwhelming a patient's immune system. Once metabolized, it works in the same way as Gilead's older intravenous COVID treatment Veklury (remdesivir), which targets virus replication through inhibition of the viral RNA polymerase. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of COVID-19.

3. Company Overview: Enanta Pharmaceuticals

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV). Enanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir).

Product Description: EDP-235

EDP-235, Enanta’s lead 3CL protease inhibitor (also known as main protease or Mpro), which has Fast Track designation from the U.S. Food and Drug Administration, was specifically designed for the treatment of COVID-19. Preclinical data show that EDP-235 potently blocks the replication of SARS-CoV-2 in multiple cellular models. For example, in Vero cells, an EC90 of 11 and 5 nanomolar were observed for the Alpha and Omicron variant, respectively, positioning EDP-235 among the most potent direct-acting antivirals currently in development for SARS-CoV-2 infection. Preclinical studies also show that EDP-235 has favorable distribution into lung cells as well as other key target tissues. In addition to SARS-CoV-2, EDP-235 has potent antiviral activity against other human coronaviruses, enabling the potential for a pan-coronavirus treatment, including possibly coronaviruses that may infect human populations in the future. The drug is currently in Phase II stage of development for the treatment of patients with COVID 19.

4. Company Overview: Sinovac Biotech

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

Product Description: SA55

SA55 is the broad-spectrum neutralizing antibody was founded by a research team led by Dr. Xiaoliang Xie, academician of the Chinese Academy of Sciences and Dr. Yunlong Cao, researcher at Peking University’s Biomedical Pioneering Innovation Center. SA55 injection is a fully humanized antibody, which is screened from the blood of recovered SARS patients who have received three doses of COVID-19 vaccine, and then recombinantly expressed. As a prevention option, they have the advantage of rapidly increasing antibody levels post-administration and enjoy a longer half-life, making them suitable for immunocompromised individuals and those who would otherwise be ineligible for vaccination. China’s National Medical Products Administration has approved SINOVAC’s SA55 Nasal Spray for clinical trial in the prevention of COVID-19 infections, in April 2023. The drug is currently in Phase II stage of development for the treatment of patients with COVID 19.

5. Company Overview: Immorna

Immorna is a rapidly expanding biotechnology company, focusing on the development of RNA-based therapeutics and vaccines. Immorna is utilizing multiple RNA platforms, including conventional, self-replicating and circular RNA. Since its founding in 2019, Immorna has built a robust CMC platform for RNA synthesis, purification, and analytical testing that is well suited for clinical and commercial development. In addition, with its state-of-the-art screening tools, Immorna has developed an arsenal of RNA delivery vehicles, including polymers and lipid nanoparticles featuring multiple proprietary ionizable cationic lipids suitable for intramuscular, intravenous and tissue-targeting delivery. Immorna has a growing intellectual property portfolio and a diverse RNA development pipeline spanning cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology, and quickly advancing its oncology drug and infectious disease vaccine candidates into clinical stages.

Product Description: JCXH-221

JCXH-221 is a mono-valent yet broadly protective mRNA-LNP vaccine. Once administered, the single chain mRNA will translate and be spontaneously assembled into multimers that contain immune epitopes from several SARS-CoV-2 strains. The multimer configuration is believed to further enhance their immunogenicity. In preclinical testing, JCXH-221 elicited robust neutralizing antibodies against an assay of viral strains, including the ancestral, Beta, Delta, Omicron BA.1, BA.2.12.1, and BA.4/5. JCXH-221 is formulated with a thermal stable nanoparticle delivery system that is stable at 2-8°C for at least 18 months. JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of this multi-center study is to assess the safety and immunogenicity of JCXH-221 in healthy adult subjects. The drug is currently in Phase I/II stage of development for the treatment of patients with COVID 19.

6. Company Overview: Immunome

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com or follow Immunome on Twitter and LinkedIn.

Product Description: IMM-BCP-01

IMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Spike protein of SARS-CoV-2, including highly conserved, subdominant epitopes, which elicits both ACE2 and non-ACE2 dependent neutralization and induces natural viral clearance mechanisms, such as antibody dependent cellular cytotoxicity, complement activation and phagocytosis. Immunome has submitted an Investigational New Drug Application with the FDA and plans to initiate a placebo-controlled dose escalation study of IMM-BCP-01 in patients infected with SARS-CoV-2. This investigational work was funded by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Defense Health Agency (DHA). The drug is currently in preclinical stage of development for the treatment of patients with COVID 19.

Further product details are provided in the report……..

COVID-19 Analytical Perspective by DelveInsight

In-depth Commercial Assessment: COVID-19 Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

COVID-19 Competitive Landscape 

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

COVID-19 Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing COVID-19 drugs?
• How many COVID-19 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for COVID-19 and their status?
• What are the key designations that have been granted to the emerging and approved drugs?